Reporting from the ESMO Congress 2021, Valentina Guarneri provides an overview of the meta-analysis data in HER2-positive early breast cancer from the neoadjuvant trastuzumab-lapatinib studies with regard to the risk of relapse and death and the optimal treatment duration of adjuvant trastuzumab. She also explores the prognostic value of immune gene-expression signatures and TILs to predict the pathological response and patient outcomes.
117O - Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomised trials - Prof Valentina Guarneri, IT
LBA11 - Individual patient data Meta-Analysis of 5 Non-Inferiority RCTs of Reduced Duration single agent adjuvant Trastuzumab in the treatment of HER2 positive Early Breast Cancer - Prof Helena Earl, GB
120MO - Prognostic value of immune gene-expression signatures (iGES) vs. tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: a combined analysis of CALGB 40601 (C40601) and PAMELA trials. - Ms. Aranzazu Fernandez-Martinez, US
This video is part of a sponsored track. The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.